Abstract P1-09-10: Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer
CF Singer(Innsbruck Medical University), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Florian Fitzal, M. Rudas(Comprehensive Cancer Center Vienna), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Martin Filipits(University of Vienna), Rupert Bartsch(Universitätszahnklinik Wien), Angelika Reiner(Donauspital), M. Balic(Innsbruck Medical University), Daniel Egle(Innsbruck Medical University), Ruth Exner(Comprehensive Cancer Center Vienna), Michael Fridrik, YY Tan(Innsbruck Medical University), C. Gruber, G.G. Steger(National Cancer Center), Monika Seifert(Innsbruck Medical University)
Cited by 2
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830